SCHOTT Pharma launches safety system: Schott Pharma stock sits 4.10 percent below its high

Published on 10/02/2026 at 14:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The 5.5 ml syringe system targets large-volume biologics. Schott Pharma stock costs EUR 24.55 on October 2, 2026, 4.10 percent below EUR 25.60.

Architektur-Render einer modernen Produktionsanlage bei Abenddämmerung — SCHOTT Pharma (DE000A3ENQ51) zeigt einen modernen Architektur-Render einer Pharmaverpackungsanlage bei Dämmerung mit großer Glasfassade, Illustration mit AI erstellt.

SCHOTT Pharma (ISIN DE000A3ENQ51) launched a 5.5 ml passive safety system with Nemera for large-volume injections, while its stock stood 4.10 percent below its 52-week high. Manufacturing Chemist reported the introduction on October 1, 2026, ahead of presentations at CPHI Milan and PDA Palm Springs.

Large-volume delivery enters the portfolio

The system combines SCHOTT Pharma's syriQ BioPure 5.5 ml prefillable glass syringe with Nemera's Safe'n'Sound passive safety device. It is designed for large-volume subcutaneous injections and is already available for technical assessment, compatibility studies, and development programs, according to Manufacturing Chemist on October 1, 2026.

The product expands SCHOTT Pharma's established prefillable syringe platform into higher-volume biologic treatments. That matters commercially because the integrated format is intended to reduce development complexity for drugmakers moving therapies toward self-administration.

Third-quarter revenue grew 10.00 percent

In the third quarter of fiscal 2026, group revenue reached EUR 281.80 million, up 10.00 percent on a reported basis and 8.30 percent at constant currencies. EBITDA was EUR 75.00 million, giving the quarter an EBITDA margin of 26.80 percent, according to Yahoo Finance in the August 12, 2026 earnings transcript.

The nine-month fiscal 2026 picture was more mixed: revenue totaled EUR 769.80 million, up 4.10 percent on a reported basis, while EBITDA fell 3.80 percent to EUR 205.30 million. The EBITDA margin declined to 26.70 percent from 28.90 percent in the comparable period, making utilization and product mix important measures for the next report.

Guidance keeps the market focused

Management confirmed fiscal 2026 revenue growth guidance of 5.00 percent to 6.00 percent at constant currencies, raised from 2.00 percent to 5.00 percent, and expects an EBITDA margin of 27.00 percent to 28.00 percent. The company also expects capital expenditures of EUR 140.00 million to EUR 160.00 million, according to Yahoo Finance.

JPMorgan initiated coverage with an Overweight rating and a EUR 27.10 price target on September 15, 2026. FinanzNachrichten reported that analyst Philip Omnou sees annual earnings growth potential of 14.00 percent through 2029. The target is 10.39 percent above the Lang & Schwarz price, using EUR 27.10 and EUR 24.55.

Stock remains below its yearly high

SCHOTT Pharma stock was trading at EUR 24.55 at Lang & Schwarz on October 2, 2026 at 2:05 p.m. CEST, up 0.70 percent versus the prior close of EUR 24.38 dated October 1, 2026. The 52-week range was EUR 12.62 to EUR 25.60, placing the reference price 4.10 percent below the high.

For investors, the central tension is clear: fiscal 2026 revenue guidance has improved, but the nine-month EBITDA margin remains below the prior-year comparison. The new delivery system adds a concrete product milestone as the company works to convert demand for biologics and home-based treatment into higher-value sales.

The further course of trading is shown by the continuously updated real-time quote of Schott Pharma stock.